皮膚B細胞リンパ腫（CBCL）治療市場レポート：2030年までの動向、予測、競合分析

皮膚B細胞リンパ腫（CBCL）治療の動向と予測

世界の皮膚B細胞リンパ腫（CBCL）治療市場は、2024年から2030年にかけてCAGR 2.3％で成長すると予測されます。この市場の主な促進要因は、先進的な標的治療の採用拡大、臨床エビデンスの実証利用の増加、さらに皮膚B細胞リンパ腫（CBCL）を治療するための新製品開発のための研究開発投資の増加です。世界の皮膚B細胞リンパ腫（CBCL）治療市場の将来は、病院・専門クリニック市場でのビジネスチャンスによって有望視されています。

皮膚B細胞リンパ腫（CBCL）治療市場の洞察

Lucintelの予測では、化学療法は、進行例に対する有効性と異なる病期への適応性から、予測期間中に最も高い成長が見込まれます。

北米は予測期間中に最も高い成長が見込まれます。

本レポートは以下の11の主要な質問に回答しています：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の皮膚B細胞リンパ腫（CBCL）治療市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の皮膚B細胞リンパ腫（CBCL）治療市場動向（2018～2023年）と予測（2024～2030年）
• タイプ別の世界の皮膚B細胞リンパ腫（CBCL）治療市場
  • 放射線療法
  • 化学療法
  • モノクローナル抗体
  • その他
• 最終用途別の世界の皮膚B細胞リンパ腫（CBCL）治療市場
  • 病院
  • 専門クリニック
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の皮膚B細胞リンパ腫（CBCL）治療市場
• 北米の皮膚B細胞リンパ腫（CBCL）治療市場
• 欧州の皮膚B細胞リンパ腫（CBCL）治療市場
• アジア太平洋の皮膚B細胞リンパ腫（CBCL）治療市場
• その他地域の皮膚B細胞リンパ腫（CBCL）治療市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • タイプ別の世界の皮膚B細胞リンパ腫（CBCL）治療市場の成長機会
  • 最終用途別の世界の皮膚B細胞リンパ腫（CBCL）治療市場の成長機会
  • 地域別の世界の皮膚B細胞リンパ腫（CBCL）治療市場の成長機会
• 世界の皮膚B細胞リンパ腫（CBCL）治療市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の皮膚B細胞リンパ腫（CBCL）治療市場の能力拡大
  • 世界の皮膚B細胞リンパ腫（CBCL）治療市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Kite Pharma
• Genentech
• Novartis
• Epizyme
• NanoString Technologies
• Amgen
• Johnson & Johnson Services

Cutaneous Bcell Lymphoma Treatment Trends and Forecast

The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets. The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030. The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

A more than 150-page report is developed to help in your business decisions.

Cutaneous Bcell Lymphoma Treatment by Segment

The study includes a forecast for the global cutaneous Bcell lymphoma treatment by type, end use, and region.

Cutaneous Bcell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Radiation Therapy
• Chemotherapy
• Monoclonal Antibodies
• Others

Cutaneous Bcell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Speciality Clinics
• Others

Cutaneous Bcell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cutaneous Bcell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cutaneous Bcell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cutaneous Bcell lymphoma treatment companies profiled in this report include-

• Kite Pharma
• Genentech
• Novartis
• Epizyme
• Nanostring Technologies
• Amgen
• Johnson & Johnson Services

Cutaneous Bcell Lymphoma Treatment Market Insights

Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

North America is expected to witness highest growth over the forecast period.

Features of the Global Cutaneous Bcell Lymphoma Treatment Market

Market Size Estimates: Cutaneous Bcell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cutaneous Bcell lymphoma treatment market size by type, end use, and region in terms of value ($B).

Regional Analysis: Cutaneous Bcell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, end use, and regions for the cutaneous Bcell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cutaneous Bcell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for cutaneous Bcell lymphoma treatment market?

Answer: The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the cutaneous Bcell lymphoma treatment market?

Answer: The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

Q3. What are the major segments for cutaneous Bcell lymphoma treatment market?

Answer: The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets.

Q4. Who are the key cutaneous Bcell lymphoma treatment market companies?

Answer: Some of the key cutaneous Bcell lymphoma treatment companies are as follows:

• Kite Pharma
• Genentech
• Novartis
• Epizyme
• Nanostring Technologies
• Amgen
• Johnson & Johnson Services

Q5. Which cutaneous Bcell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

Q6. In cutaneous Bcell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cutaneous Bcell lymphoma treatment market by type (radiation therapy, chemotherapy, monoclonal antibodies, and others), end use (hospitals, speciality clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cutaneous Bcell Lymphoma Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Cutaneous Bcell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Cutaneous Bcell Lymphoma Treatment Market by Type
  • 3.3.1: Radiation Therapy
  • 3.3.2: Chemotherapy
  • 3.3.3: Monoclonal Antibodies
  • 3.3.4: Others
• 3.4: Global Cutaneous Bcell Lymphoma Treatment Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Speciality Clinics
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Cutaneous Bcell Lymphoma Treatment Market by Region
• 4.2: North American Cutaneous Bcell Lymphoma Treatment Market
  • 4.2.2: North American Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
• 4.3: European Cutaneous Bcell Lymphoma Treatment Market
  • 4.3.1: European Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
  • 4.3.2: European Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
• 4.4: APAC Cutaneous Bcell Lymphoma Treatment Market
  • 4.4.1: APAC Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
  • 4.4.2: APAC Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
• 4.5: ROW Cutaneous Bcell Lymphoma Treatment Market
  • 4.5.1: ROW Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
  • 4.5.2: ROW Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by End Use
  • 6.1.3: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Region
• 6.2: Emerging Trends in the Global Cutaneous Bcell Lymphoma Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cutaneous Bcell Lymphoma Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cutaneous Bcell Lymphoma Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Kite Pharma
• 7.2: Genentech
• 7.3: Novartis
• 7.4: Epizyme
• 7.5: NanoString Technologies
• 7.6: Amgen
• 7.7: Johnson & Johnson Services